MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Iovance Biotherapeutics Inc

Geschlossen

BrancheGesundheitswesen

2.26 4.15

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.16

Max

2.33

Schlüsselkennzahlen

By Trading Economics

Einkommen

4.5M

-112M

Verkäufe

11M

60M

Gewinnspanne

-186.246

Angestellte

838

EBITDA

8.3M

-102M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+389.45% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-145M

800M

Vorheriger Eröffnungskurs

-1.89

Vorheriger Schlusskurs

2.26

Nachrichtenstimmung

By Acuity

100%

0%

364 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

Iovance Biotherapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

8. Okt. 2025, 20:45 UTC

Ergebnisse

Costco Wholesale Sales Climb in September, Early October

8. Okt. 2025, 20:12 UTC

Wichtige Markttreiber
Akquisitionen, Fusionen, Übernahmen

TaskUs Shares Fall After Holders Reject Take-Private Deal

8. Okt. 2025, 16:39 UTC

Wichtige Markttreiber

Mining Shares Rise as Gold Prices Soar

8. Okt. 2025, 23:45 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

8. Okt. 2025, 23:43 UTC

Market Talk

Gold Falls on Possible Profit-Taking -- Market Talk

8. Okt. 2025, 23:18 UTC

Akquisitionen, Fusionen, Übernahmen

JD Logistics to Finance Acquisition Using Internal Funds

8. Okt. 2025, 23:17 UTC

Akquisitionen, Fusionen, Übernahmen

JD Logistics to Buy On-Demand Delivery Services Business for US$270.0M

8. Okt. 2025, 23:16 UTC

Akquisitionen, Fusionen, Übernahmen

JD Logistics to Buy JD.com's On-Demand Delivery Services Business Dajiang and Dasheng

8. Okt. 2025, 21:54 UTC

Market Talk
Ergebnisse

James Hardie Could Beat Annual Earnings Goal -- Market Talk

8. Okt. 2025, 21:30 UTC

Market Talk

Boab Metals Bull Delivers Second Upgrade in a Month -- Market Talk

8. Okt. 2025, 21:26 UTC

Market Talk
Ergebnisse

Transurban's 1Q Traffic Growth Beats Hopes -- Market Talk

8. Okt. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8. Okt. 2025, 19:15 UTC

Market Talk

Geopolitical Risk Supports Gains in Oil Futures -- Market Talk

8. Okt. 2025, 19:01 UTC

Market Talk

U.S. Natural Gas Futures Pull Back Ahead of Storage Data -- Market Talk

8. Okt. 2025, 18:47 UTC

Market Talk

Coca-Cola North America Sales Buoy International Weakness -- Market Talk

8. Okt. 2025, 18:46 UTC

Akquisitionen, Fusionen, Übernahmen

TaskUs: Neither Party Will Be Required to Pay Termination Fee as Result of Planned Mutual Decision to Terminate

8. Okt. 2025, 18:46 UTC

Akquisitionen, Fusionen, Übernahmen

TaskUs Will Remain a Publicly Traded Co >TASK

8. Okt. 2025, 18:46 UTC

Akquisitionen, Fusionen, Übernahmen

TaskUs Does Not Plan to Convene Another Special Meeting of Stockholders >TASK

8. Okt. 2025, 18:45 UTC

Akquisitionen, Fusionen, Übernahmen

TaskUs Didn't Receive Votes Necessary to Approve Transaction Agreement With Affil of Blackstone >TASK

8. Okt. 2025, 18:07 UTC

Market Talk

Mexico's Inflation Seen Edging Up in September -- Market Talk

8. Okt. 2025, 16:20 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Energy & Utilities Roundup: Market Talk

8. Okt. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

8. Okt. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8. Okt. 2025, 15:57 UTC

Market Talk

Oil Rises Despite U.S. Crude Stockpiles Build -- Market Talk

8. Okt. 2025, 15:56 UTC

Market Talk

Teck Resources' Chile Mine Issues Appear Transitory -- Market Talk

8. Okt. 2025, 15:53 UTC

Market Talk

Argentine Sovereign Debt Seen as Attractive -- Market Talk

8. Okt. 2025, 15:44 UTC

Akquisitionen, Fusionen, Übernahmen

Staar Surgical: Broadwood's Proposal to Vote Down Merger Could Allow It to Take Control Without Paying Any Premium

8. Okt. 2025, 15:44 UTC

Akquisitionen, Fusionen, Übernahmen

Staar Surgical Board and Management Disagree With Recommendation Issued by Glass Lewis >STAA

8. Okt. 2025, 15:43 UTC

Akquisitionen, Fusionen, Übernahmen

STAAR Surgical Board Reiterates Unanimous Recommendation Holders Vote for Alcon Merger

8. Okt. 2025, 15:42 UTC

Akquisitionen, Fusionen, Übernahmen

Oracle Is a Buy-the-Dip Opportunity, Analyst Says. How the Stock Could Rise 23%. -- Barrons.com

Peer-Vergleich

Kursveränderung

Iovance Biotherapeutics Inc Prognose

Kursziel

By TipRanks

389.45% Vorteil

12-Monats-Prognose

Durchschnitt 10.67 USD  389.45%

Hoch 20 USD

Tief 1 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Iovance Biotherapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

8 ratings

5

Buy

2

Halten

1

Sell

Technischer Score

By Trading Central

3.0208 / 3.5Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Weak Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
help-icon Live chat